Second-Line Liso-Cel CAR T-Cell Therapy Shows EFS Benefit for R/R LBCL

EBMT 2022: Updated results of a study investigating CAR T therapy Lisocabtagene maraleucel as second line treatment for relapsed large cell lymphomas.